New technologies to accelerate ADC design

ADCs represent a new era in targeted cancer therapy, with 15 approved drugs currently on the market. However, more than 100 discontinued programs and a similar number of active clinical trials also underscore the challenges in ADC design. Gaining a deeper understanding of the mechanisms and factors contributing to ADC efficacy and toxicity is essential for accelerating drug development. AI-based tools can help streamline this process by scaling up hypothesis exploration, optimizing antibody and payload selection for patients, and designing linkers to complete the molecules.